Rituximab Biosimilar N297A Research Grade

Human

CD20

1.0 - 5.0 mg/ml

Human IgG1 (N297A)-Kappa

CHO Cells

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Rituximab.

Blue ice

CD20 is a B-lineage surface antigen central to research on B-cell depletion and lymphoid malignancies. Engineered with the aglycosylating N297A mutation to remove Fc glycan-dependent effector function, this research-grade anti-human CD20 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of rituximab built around the CD20 target for research use only. Produced to in vivo standards as an ultra-pure, low-endotoxin human IgG1-kappa, it is supplied in scalable milligram to gram quantities for high-throughput and bulk laboratories. The antibody is suited to binding and blocking assays, in vitro screening, and in vivo B-cell biology models where effector function must be controlled.

MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7

P11836

ICH3001-100ml ICH3002-100ml ICH3003-100ml

https://www.imgt.org/mAb-DB/

Q: Is the Rituximab biosimilar available in gram quantities?

A: Yes - it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this Rituximab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Rituximab biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar analog of Rituximab that binds human CD20; for research use only (RUO).